The US Patent and Trademark Office (USPTO) has issued a notice of allowance for CytRx Corporation's patent application covering a pharmaceutical composition of tamibarotene in capsule form.
Tamibarotene is an orally available, rationally designed, synthetic retinoid compound that was designed to be more potent than the chemotherapeutic agent all-trans retinoic acid (ATRA), which selectively bind to specific molecular receptors. The patent once issued will expire in 2028.
CytRx CEO Steven Kriegsman said the company is highly optimistic about tamibarotene's prospects for improving the treatment of certain cancers, and strengthening the intellectual property position for the oncology asset.
"Last month we announced a major milestone in our late-stage clinical trial with tamibarotene in NSCLC. An approval to market tamibarotene for this indication alone could represent a blockbuster opportunity for CytRx," Kriegsman added.
CytRx is at present conducting a Phase 2b global trial with tamibarotene as a first-line treatment for non-small-cell lung cancer and a Phase 2 clinical trial with tamibarotene as a treatment for acute promyelocytic leukemia.
